The speaker will highlight the urgent and growing global threat posed by antimicrobial resistance (AMR) in tuberculosis (TB) and other non-tuberculous mycobacterial (NTM) infections. This talk will address the major challenges in developing new therapeutic strategies to target the varied physiological states of these resilient pathogens and their exceptional ability to evade host defence mechanisms across human, animal, and environmental settings, within biofilm-forming microbiomes. Drawing on recent research findings, the seminar will discuss the validation of novel therapeutic targets that could accelerate drug design and discovery efforts. In particular, it will highlight promising work on the repurposing of carprofen, a non-steroidal anti-inflammatory drug, to help reverse drug resistance in TB and NTM diseases.​
This interdisciplinary seminar is designed to engage a broad audience, including researchers in basic science, public health professionals, clinicians, and industry experts, all united by a shared interest in tackling one of the most pressing health threats of our time.​